(Q348260)

English

adalimumab

pharmaceutical drug

D2E7
Ig gamma-1 chain C region
LU-200134
FKB327
Humira®
Humira

In more languages

default for all languages

No label defined

No description defined

Statements

type of chemical entity

0 references

chemical compound

0 references

1 reference

Adalimumab (English)

language of work or name

publication date

17 November 2015

chemical structure

Adalimumab structure.svg
726 × 648; 5 KB

0 references

defined daily dose

2.9 milligram

route of administration

parenteral route of administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=L04AB04

active ingredient in

1 reference

European Medicines Agency product number

EMEA/H/C/000481

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000481/human_med_000822.jsp

22 March 2017

1 reference

European Medicines Agency product number

EMEA/H/C/000482

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000482/human_med_001112.jsp

22 March 2017

World Health Organisation international non-proprietary name

adalimumab (English)

1 reference

language of work or name

Adalimumab (English)

19 January 2016

medical condition treated

rheumatoid arthritis

1 reference

language of work or name

13 December 2016

1 reference

Drug Indications Extracted from FAERS

2 October 2018

pyoderma gangrenosum

1 reference

Drug Indications Extracted from FAERS

2 October 2018

osteoarthritis susceptibility 1

1 reference

Drug Indications Extracted from FAERS

2 October 2018

pityriasis rubra pilaris

1 reference

Drug Indications Extracted from FAERS

2 October 2018

ankylosing spondylitis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

reactive arthritis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

granuloma annulare

1 reference

Drug Indications Extracted from FAERS

2 October 2018

Sjögren's syndrome

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

ulcerative colitis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

Behçet's disease

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

guttate psoriasis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

irritable bowel syndrome

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

legal status (medicine)

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

Australian pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category B

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category B

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Adalimumab

10 February 2017

has characteristic

biopharmaceutical

1 reference

Adalimumab (English)

language of work or name

publication date

17 November 2015

subject has role

immunologic factor

1 reference

5 March 2018

disease-modifying antirheumatic drug

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

anti-inflammatory agent

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

monoclonal antibody

2 references

language of work or name

Adalimumab (English)

publication date

17 November 2015

27 February 2018

Autoinjector with Amgevita by Amgen (Adalimumab)-6390.jpg
4,181 × 2,352; 3.29 MB

0 references

Commons category

Adalimumab

0 references

Identifiers

CAS Registry Number

1 reference

language of work or name

Adalimumab (English)

publication date

17 November 2015

1 reference

language of work or name

Adalimumab (English)

19 January 2016

1 reference

Hazardous Substances Data Bank

publication date

28 October 2019

Adalimumab (English)

10 May 2021

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer (English)

CAS no.: 331731-18-1 (English)

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer (English)

CAS no.: 331731-18-1 (English)

1 reference

language of work or name

Adalimumab (English)

publication date

17 November 2015

World Health Organisation international non-proprietary name numeric ID

0 references

Guide to Pharmacology Ligand ID

0 references

MeSH descriptor ID

subject named as

Adalimumab

0 references

D12.776.124.486.485.114.224.060.250

0 references

D12.776.124.790.651.114.224.060.250

0 references

D12.776.377.715.548.114.224.200.250

0 references

1 reference

26 February 2018

0 references

1 reference

language of work or name

ADALIMUMAB (English)

19 January 2016

MedlinePlus drug identifier

0 references

PatientsLikeMe treatment ID

0 references

1 reference

language of work or name

ADALIMUMAB (English)

19 January 2016

1 reference

imported from Wikimedia project

English Wikipedia

1 reference

6 April 2020

0 references

electronic Essential Medicines List medicine ID

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

ScienceDirect topic ID

agricultural-and-biological-sciences/adalimumab

0 references

1 reference

based on heuristic

inferred by common MeSH mappings on source and on Wikidata

25 May 2023

WikiProjectMed ID

0 references

Sitelinks

Wikipedia(28 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Adalimumab

Retrieved from "https://www.wikidata.org/w/index.php?title=Q348260&oldid=2190009903"